See more : Public Financial Holdings Limited (0626.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Selecta Biosciences, Inc. (SELB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Selecta Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hangzhou Century Co., Ltd. (300078.SZ) Income Statement Analysis – Financial Results
- Zeon Corporation (ZEOOY) Income Statement Analysis – Financial Results
- Dickson Concepts (International) Limited (0113.HK) Income Statement Analysis – Financial Results
- Kwong Man Kee Group Limited (8023.HK) Income Statement Analysis – Financial Results
- Olympus Corporation (OCPNY) Income Statement Analysis – Financial Results
Selecta Biosciences, Inc. (SELB)
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 0.00 | 72.38M | 68.74M | 54.51M | 42.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 38.40M | 16.34M | -37.91M | -36.07M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 0.00% | 34.66% | 19.21% | -228.40% | -540.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | -1.31M | 10.00K | -152.00K | 4.00K | -26.00K | -44.00K |
| Operating Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 958.00K | 2.80M | 1.30M | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | -2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 764.00K | 1.62M | 15.00K | 89.00K | -1.31M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -86.42M | 16.16M | -4.58M | -56.73M | -53.76M | -65.01M | -63.94M | -34.67M | -24.29M | -14.58M |
| EBITDA Ratio | 0.00% | 14.58% | -5.39% | -341.82% | -805.17% | -7,199.56% | -30,886.96% | -428.88% | -404.03% | -479.57% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | 0.00% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | 0.00% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | 19.00M | -609.00K | 15.97M | 911.00K | -1.81M | 1.18M | 304.00K | 455.00K | 922.00K | 508.00K |
| Net Income | -219.71M | 35.38M | -25.69M | -69.79M | -53.54M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | 0.00% | 31.94% | -30.19% | -420.48% | -801.80% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | 0.00 | 0.24 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| EPS Diluted | 0.00 | 0.10 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| Weighted Avg Shares Out | 155.11B | 144.76M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 155.11B | 145.87M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
4 Hot Penny Stocks To Watch With News This Week
Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports